Overview: Haloperidol TestIntroduction: The Haloperidol Test measures haloperidol levels to monitor antipsychotic treatment, preventing psychosis or side effects. Following 2023 APA guidelines, it uses an immunoassay for high sensitivity, aiding in drug monitoring. This test is critical for guiding dose adjustments, ensuring therapeutic efficacy, and improving outcomes in toxicology for patients on haloperidol therapy for conditions like schizophrenia.
Other Names: Haloperidol Assay, Antipsychotic Level Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Haloperidol monitoring began in the 1970s with antipsychotic research. Immunoassays improved in the 1990s, enhancing accuracy for therapeutic drug monitoring.
Purpose: Monitors haloperidol levels, guides dose adjustments, and prevents psychosis or side effects in patients on antipsychotic therapy.
Test Parameters: 1. Haloperidol
Pretest Condition: No fasting required. Collect serum or plasma at trough levels (pre-dose). Report symptoms like psychosis or side effects, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document psychosis, side effects (e.g., extrapyramidal symptoms), or history of antipsychotic use. Include current medications and adherence history.
Consent: Written consent required, detailing the tests purpose, monitoring implications, and potential need for dose adjustments.
Procedural Considerations: Uses an immunoassay to measure haloperidol levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Timing of sample collection, hemolysis, or drug interactions (e.g., CYP3A4 inhibitors) can affect results. Non-adherence may skew levels.
Clinical Significance: Therapeutic haloperidol levels ensure efficacy, while subtherapeutic or toxic levels prompt dose adjustments. Abnormal levels may indicate non-adherence or toxicity.
Specialist Consultation: Consult a psychiatrist for result interpretation and treatment adjustments.
Additional Supporting Tests: Liver function tests, ECG, or other antipsychotic level tests to monitor overall treatment safety.
Test Limitations: Results depend on timing and adherence. Drug interactions may affect levels, requiring clinical correlation.
References: APA Antipsychotic Guidelines, 2023; American Journal of Psychiatry, Kane JM, 2022.
